Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the...

Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for
the Second Quarter Ended June 30, 2008

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc.
(Nasdaq: OREX), a biopharmaceutical company focused on the treatment of
central nervous system disorders, including obesity, will announce financial
results for its second quarter ended June 30, 2008, on Thursday, August 7,
2008, after the markets close. The announcement will be followed by a live
webcast and conference call at 2:00 p.m. Pacific Time.
Orexigen management will host the call and webcast to discuss results for
the second quarter ended June 30, 2008, and recent business highlights. The
live call may be accessed by phone by calling (800) 860-2442 (domestic) or
(412) 858-4600 (international). The webcast can be accessed live on the
investor relations section of the Company's Web site at
http://www.orexigen.com and will be archived for 14 days following the call.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
development of pharmaceutical product candidates for the treatment of central
nervous system disorders, including obesity. The Company's lead combination
product candidates targeted for obesity are Contrave(R), which is in Phase III
clinical trials, and Empatic(TM), which is in the later stages of Phase II
clinical development. Both product candidates take advantage of the Company's
understanding of how the brain appears to regulate appetite and energy
expenditure, as well as the mechanisms that come into play to limit weight
loss over time. Each product candidate is designed to act on a specific group
of neurons in the central nervous system with the goal of achieving appetite
suppression and sustained weight loss. Further information about the Company
can be found at http://www.orexigen.com.
SOURCE Orexigen Therapeutics, Inc.

Graham Cooper of Orexigen, +1-858-875-8600; or Media, Liz Frank,
+1-212-301-7216, for Orexigen